Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock Holdings Cut by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC lessened its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 21.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 244,538 shares of the company's stock after selling 65,076 shares during the quarter. Centessa Pharmaceuticals accounts for approximately 3.4% of Ally Bridge Group NY LLC's holdings, making the stock its 10th largest holding. Ally Bridge Group NY LLC owned 0.19% of Centessa Pharmaceuticals worth $4,096,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC boosted its position in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after buying an additional 865 shares during the last quarter. Barclays PLC grew its position in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after purchasing an additional 5,316 shares during the period. XTX Topco Ltd raised its stake in shares of Centessa Pharmaceuticals by 122.9% during the 4th quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock valued at $380,000 after buying an additional 12,506 shares during the last quarter. Finally, Voya Investment Management LLC acquired a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $497,000. Hedge funds and other institutional investors own 82.01% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on CNTA shares. Morgan Stanley reissued an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating on the stock. Guggenheim restated a "buy" rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Piper Sandler began coverage on shares of Centessa Pharmaceuticals in a research report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of "Buy" and a consensus price target of $27.71.

Centessa Pharmaceuticals Price Performance

CNTA stock traded down $1.57 during trading on Tuesday, hitting $12.00. The stock had a trading volume of 1,051,567 shares, compared to its average volume of 617,378. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The company's 50-day moving average price is $14.13 and its two-hundred day moving average price is $15.77. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The stock has a market capitalization of $1.60 billion, a P/E ratio of -7.84 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. As a group, research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In other news, General Counsel Iqbal J. Hussain sold 2,080 shares of the company's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $14.01, for a total value of $29,140.80. Following the completion of the sale, the general counsel now directly owns 105,386 shares in the company, valued at $1,476,457.86. This represents a 1.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Karen M. Anderson sold 30,526 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $19.03, for a total value of $580,909.78. Following the transaction, the insider now owns 54,322 shares in the company, valued at approximately $1,033,747.66. The trade was a 35.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 202,353 shares of company stock valued at $3,286,478. Corporate insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.